News

Novo Nordisk, Septerna sign $2.2B deal to develop weight-loss pill
Pharmaceutical giant Novo Nordisk (NVO) inks a $2.2 billion deal with biotech company Septerna (SEPN) to develop a GLP-1 ...
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.
Zacks Investment Research on MSN22h
Lilly Down 17% Since Q1 Results: Should You Buy the Dip in LLY Stock?
Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed ...